Skip to main content
Clinical Trials/NCT06642519
NCT06642519Enrolling By InvitationNot Applicable

Adaptive Cortical Neuromodulation Using a Brain-machine Interface to Treat Freezing of Gait in Parkinson's Disease.

University of Toronto2 sites in 1 country10 target enrollmentStarted: April 10, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
10
Locations
2
Primary Endpoint
Number and Duration FOG episodes

Study Overview

Brief Summary

Gait problems in Parkinson's disease (PD), especially freezing of gait (FOG), greatly affect quality of life. While deep brain stimulation (DBS) is a highly effective treatment for many motor symptoms of PD, it is less effective for, or can even worsen, gait issues. The primary motor cortex (M1) plays a crucial role in the network that controls gait, particularly in initiating movement. Changes in local field potentials (LFPs) from the subthalamic nucleus (STN) are associated with different aspects of gait. However, detecting abnormal brain activity related to FOG requires a method called electrocorticography (ECoG), which has revealed that during FOG, there is increased beta-gamma phase amplitude coupling (PAC) in the M1.

Brain-machine interfaces (BMIs) have shown promise in understanding motor functions by decoding brain activity. It is believed that BMIs could provide both accurate indicators of FOG and targeted treatments for it in PD.

Our objectives are to use a high-density ECoG-based BMI to both record and stimulate brain activity during real-world gait and FOG in PD patients who are undergoing standard DBS procedures. Our goals are to improve our understanding of the brain's role in FOG and normal gait in PD and to develop new treatments based on cortical stimulation.

Aim 1 - Identify gait biomarkers: brain activity from the M1/SMA cortex during different phases of walking and during FOG episodes, both with and without medication will be recorded. Machine learning will be used to identify the brain patterns linked to FOG.

Aim 2 - Use cortical stimulation to stop FOG: Cortical stimulation and its effects on leg and trunk movements will be studied by measuring muscle activity, movement, and posture during different states, such as resting, standing, walking, and during FOG episodes. The type of stimulation which is most effective at stopping FOG will be identified.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • PD fulfilling standard criteria for bilateral STN/GPi DBS surgery
  • Debilitating FOG in the off-medication condition with only partial response to levodopa (defined as the witnessed occurrence of FOG during the on phase of the pre-DBS L-dopa challenge)
  • Clinically established FOG (i.e. reported by patient/caregiver AND seen by the examiner in the clinic)
  • Able to provide informed consent, comply with study protocol

Exclusion Criteria

  • Prior ischemic stroke, intracranial hemorrhage, or intracerebral mass
  • Previous brain surgery
  • Other disorders potentially biasing assessment
  • Absence of FOG in the medication on condition (a population already manageable with current standard of treatment).

Outcomes

Primary Outcomes

Number and Duration FOG episodes

Time Frame: 7-day experiment

The number and duration of FOG episodes either with or without stimulation, including the number/duration of FOG episodes with optimal stimulation.

Secondary Outcomes

  • Measurement of Chronic Coupling between Cortex and Basal Ganglia(7-day experiment)
  • Exploring BMI Control to Trigger and Study FOG(7-day experiment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alfonso Fasano

Professor

University of Toronto

Study Sites (2)

Loading locations...

Similar Trials